Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Her2 Mutation-positive Nsclc
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy
2. Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s HER2 status
3. Life expectancy of at least 12 weeks at the start of treatment

You may not be eligible for this study if the following are true:

1. Major surgery performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
2. Treatment with a systemic anti-cancer therapy or investigational drug within 21 days of the first treatment
3. Previous treatment with any TKI targeting HER2

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies